Y. Kawakita

Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model

T. Ishikawa, Y. Ohta, Akiko Nakayama, 2013, Journal of Cancer.

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

T. Taniguchi, Toshimasa Tanaka, J. Yano, 2011, Journal of medicinal chemistry.

Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.

R. Nishigaki, T. Miyazaki, Naoki Tomita, 2017, Bioorganic & medicinal chemistry.

Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.

Toshimasa Tanaka, T. Ohashi, T. Ishikawa, 2012, Journal of medicinal chemistry.

Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors.

Yoshikazu Ohta, Tomoyasu Ishikawa, Terufumi Takagi, 2013, ACS medicinal chemistry letters.

Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.

Tomoaki Hasui, M. Fushimi, K. Saikatendu, 2019, Journal of medicinal chemistry.

Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors.

Tomohiro Ohashi, Yoshikazu Ohta, Tomoyasu Ishikawa, 2013, Bioorganic & medicinal chemistry.

Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.

Toshimasa Tanaka, Y. Ikeda, T. Ishikawa, 2012, Bioorganic & medicinal chemistry.